Figure 6. High methylation of Fuz promoter associated with poor survival probabilities in HNSC and LUAD patients, and Fuz promoter methylation level was significantly upregulated in tumor samples from ESCA, HNSC and LUAD patients. (A) Difference in Fuz promoter methylation level did not cause a significant alteration of survival probability in ESCA patients. (B, C) High Fuz promoter methylation leads to poor overall survival in HNSC (B) and LUAD (C) patients. (D, E) The methylation level of Fuz at cg11398523 site was significantly upregulated in ESCA (D) and HNSC (E) patient tumor samples. (F) The methylation level of Fuz at cg22708738 site was significantly upregulated in LUAD patient tumor samples.